Hyperleukocytic acute leukemia (HLAL) is a medical emergency of hematological malignancy, which is defined as high white blood cell (WBC) counts exceeding $10^9$ \text{L}^{-1} with very high early complications and mortality rate [1]. The incidence of HLAL in acute myeloid leukemia (AML) and acute lymphocytic leukemia (ALL) is about 5–20% and 18.6%, respectively [2]. Hyperleukocytosis (HL) is a high-risk situation in leukemia, which is associated with leukostasis syndrome, tumour lysis syndrome (TLS), and disseminated intravascular coagulopathy (DIC). It is also independently associated with shorter relapse-free survival and a lower response to initial chemotherapy [3, 4]. Thus, patients with HL share an increased risk of death during the initial phase of the disease. HLAL is significantly more active in bone marrow proliferation than non-HLAL patients, which is positively correlated with peripheral blood

1. Introduction

Hyperleukocytic acute leukemia (HLAL) is a medical emergency of hematological malignancy, which is defined as high white blood cell (WBC) counts exceeding $10^9$ \text{L}^{-1} with very high early complications and mortality rate [1]. The incidence of HLAL in acute myeloid leukemia (AML) and acute lymphocytic leukemia (ALL) is about 5–20% and 18.6%, respectively [2]. Hyperleukocytosis (HL) is a high-risk situation in leukemia, which is associated with leukostasis syndrome, tumour lysis syndrome (TLS), and disseminated intravascular coagulopathy (DIC). It is also independently associated with shorter relapse-free survival and a lower response to initial chemotherapy [3, 4]. Thus, patients with HL share an increased risk of death during the initial phase of the disease. HLAL is significantly more active in bone marrow proliferation than non-HLAL patients, which is positively correlated with peripheral blood
white blood cell count and has lower hemoglobin and platelets.

The normal hematopoietic process requires complex two-way interactions between hematopoietic stem cells and the hematopoietic microenvironment [5–7]. These interactions are essential for maintaining the normal function of normal hematopoietic stem cells. Once the structural or functional disorder of the hematopoietic stem cell niche affects the self-renewal and normal multilineage differentiation process of hematopoietic stem cells, it closely relates to the occurrence and development of blood system diseases.

During leukemogenesis, leukemia cells induce molecular changes in distinct hematopoietic and nonhematopoietic cell populations in the bone marrow niche [8]. The genetic and epigenetic changes accumulating in preleukemic hematopoietic stem cells (HSCs) contribute to inducing abnormal clonal proliferation and differentiation of HSCs and disrupting normal hematopoiesis [9]. In addition, bone marrow mesenchymal stem cells (BM-MSCs) play a critical role in maintaining normal hematopoiesis and the process of mobilization and homing, and in drug resistance and clinical recurrence, by secreting various cytokines, chemokines, and signaling molecules [10]. It is commonly acknowledged that exosomes are secreted by a variety of cells such as tumor cells and can induce the tumor microenvironment (TME) to support tumor growth and metastasis [11, 12]. AML cells remodel the bone marrow niche leukemia-permissive microenvironment and inhibit hematopoiesis by deriving exosomes to BM-MSCs [13]. K562 cell-derived exosomes can affect the genes involved in hematopoietic developmental pathways and immune responses of BM-MSCs and macrophages [14]. However, little is known about how HLAL-derived exosomes effect the HSCs and BM-MSCs.

Exosome (Exo) are extracellular membrane vesicles with a diameter ranging from 30 to 150 nm and carry proteins, RNA, DNA, and noncoding RNAs which participate in intracellular communication [15]. Recently, accumulating studies demonstrate that exosome transfer MicroRNAs (miRNAs) under physiological and pathological conditions [16]. miRNAs are ~22-nucleotide (nt) noncoding RNAs involved in the regulation of gene expression to coordinate a broad spectrum of biological processes. A study conducted by Zhao et al. demonstrated that AML cell-derived exosomal miR-4532 disrupt normal hematopoiesis in HSCs [17]. Silencing miR-181a from pediatric ALL (PALL) circulating exosomes reverses Exo-PALL-induced leukemic cell proliferation and gene regulation in vitro [18]. In this paper, we have investigated the effects of circulating exosomes from HLAL patients and examined the expression of miRNAs in HLAL-driven exosomes. The main contributions of this article are given as follows:

1. To evaluate and explore the effects of miR-125b, which is carried by HLAL-derived exosomes, on the hematopoietic function of HSCs and BM-MSCs
2. To identify miR-125b-5p as a crucial component and if exosomal miR-125b-5p induced functional loss of HSCs and altered the hematopoiesis supports of BM-MSCs
3. To isolate exosomes from the peripheral blood of HLAL patients and healthy volunteers

The rest of this manuscript is organized as follows. In section 2, the proposed method along with the ethical statement is described in detail.

2. Proposed Methods

In this section, we have provided a detailed description of the proposed scheme and how it is different from existing scheme and, additionally, why the proposed scheme is more convincing and useful to resolve the aforementioned issue associated with the existing state of the art techniques.

2.1. Ethics Statement. Generally, a signed consent form is needed if an organization is collecting peripheral blood samples of hyperleukocytic acute leukemia (HLAL) patients and healthy controls and cord blood samples of full-term pregnancy. Various experiments, which were performed during this study, were reviewed and approved by the Ethics Committee of the First People’s Hospital of Yunnan Province, and all experiments were carried out in accordance with the Declaration of Helsinki.

2.2. Cord Blood CD34+HSC Separation. Using density gradient centrifugation, mononuclear cells in cord blood were separated and washed with PBS buffer (Sangon Biotech, Shanghai, China). According to the requirements of instructions, we used the CD34 positive sorting kit (Miltenyi Biotec, Bergisch, Gladbach, Germany) to sort out CD34+ cells on the magnetic bead sorter and resuspended the cells in Iscove’s Modified Dulbecco’s Medium (IMDM, Invitrogen, Carlsbad, CA, USA) containing 15% fetal bovine serum (FBS, Gibco, Grand Island, NY, USA) and 100 U/ml penicillin-streptomycin (Gibco, Grand Island, NY, USA).

2.3. Exosome Isolation, Characterization, and Labeling

2.3.1. Isolation. Centrifugation at 500g for 20 min at 4°C was performed to remove cells, followed by centrifugation at 10,000g for 30 min to remove cell debris and at 100,000×g for 90 min to collect exosomes, and the precipitate was washed twice with PBS.

2.3.2. Characterization. We used transmission electron microscopy (TEM, Thermo Fisher Scientific, Waltham, MA, USA) to observe and identify the morphology of exosomes and evaluate the size of exosomes through nanoparticle tracking analysis (NTA, Malvern Panalytical, Westborough, MA, USA).

2.3.3. Labeling. The exosomal precipitate is dissolved in RIPA buffer (Sigma-Aldrich, St. Louis, MO, USA), and the BCA kit (TaKaRa, Tokyo, Japan) is used for protein quantification. TSG101 (1:1000) and CD63 (1:1000) antibodies (Abcam, Cambridge, MA, USA) are used for western blot
For color development. Images were collected in a gel imaging system.

2.8. Colony-Forming Units (CFUs). The exosomes isolated from the peripheral blood of HLAL patients and healthy controls were cultured with HSCs or BM-MSCs, and CFU analysis was performed using methylcellulose complete medium (STEMCELL Technologies, Vancouver, BC, Canada). After 48 h, cells were recovered, resuspended in a methylcellulose complete medium at a density of 5000 cells and inoculated into a Petri dish, and incubated for 7 days at 37°C, 5% CO₂, and ≥95% humidity. The colonies were observed and counted under a microscope.

2.9. Dual-Luciferase Reporter Gene. Wild-type (wt) or mutant fragments (mut) of the BAK1 3′ untranslated region (3′ UTR) were synthesized and inserted into the PGL4 vector (Promega, Madison, WI, USA) to obtain the sequences of BAK1-wt and BAK1-mut. The miR-125b mimic or negative control (NC) mimic and BAK1-wt or BAK1-mut recombinant plasmid were transfected into the cells, after 48 hours of transfection, the cells were lysed, and the luciferase activity was detected according to the instructions of the dual-luciferase reporter gene system kit (Promega, Madison, WI, USA).

2.10. Statistical Analysis. Statistical analysis was performed using the GraphPad Prism5.0 software, and the data were expressed as mean ± standard deviation (SD). The unpaired t-test was used for comparison between the two groups. A value of \( p < 0.05 \) was considered to be statistically significant.

3. Experimental Results and Observations

This section describes various results which are obtained through a sophisticated set of experiments performed in the realistic environment of hospital. Additionally, proper consensus was taken from patients or normal persons who were willing to voluntarily participate in the experimental process. Details of various results are given below.

3.1. Isolation and Characterization of Circulating Exosomes.

We have profiled plasma exosomal miRNAs of HLAL patients, as well as healthy individuals, as normal control and then isolated microvesicle from peripheral blood by differential centrifugation. The exosome separation was confirmed by TEM (as shown in Figure 1(a)), and both HLAL patients’ and healthy volunteers’ exosomes presented with saucer-shaped stereochemical structures with a clear membrane. In addition, the NTA determined all particles have an average diameter of approximately 80 nm (as shown in Figure 1(b)). Western blot analysis of the specific exosome markers CD63 and TSG101 in the extracts confirmed the presence of exosomes (as shown in Figures 1(c) and 1(d)). The exosomal miRNAs expression was sequenced, and the results are presented in Figure 1(e)), which revealed that
Figure 1: Continued.
miR-125b-5p was upregulated in HLAL patients circulating exosomes.

3.2. Effects of HLAL-Derived Circulating Exosomes on HSCs and BM-MSCs. We speculated that HLAL-associated exosomes were absorbed by HSCs and BM-MSCs and then mediated the development of HLAL. The HSCs and BM-MSCs were cocultured with CFSE-labeled exosomes for 48 hours, and internalization of exosome was detected under the fluorescence microscope (Figure 2(a)). The counts of colony forming unit (CFU) in HSCs were all lower in HSCs treated with HLAL-exo than that in HSCs treated with no exosome and normal exosome; the results of CFU in BM-MSCs demonstrated that both HLAL-exo and normal-exo have no influence on the colony-formation ability of BM-MSCs (as shown in Figure 2(b)). Next, effects of exosome on the protein levels of the gene involved in hematopoiesis regulation were detected. The results of western blot showed that HLAL-exo downregulated the levels of α-globulin, γ-globulin, and CSF2, but upregulated the levels of chemokines CXCR4 (as shown in Figure 2(c)). Furthermore, HLAL-exo obviously promoted the expression of DKK1, while CXCL12, IGF1 and SCF were inhibited (as shown in Figure 2(d)). Hence, our results suggested that HLAL-derived exosomes can regulate the hematopoietic differentiation of HSCs and the hematopoiesis-supportive function of BM-MSCs.

3.3. HLAL-Exo Influences HSCs and BM-MSCs by Delivering miR-125b. Thus, we analyzed differentially expressed exosomal miRNAs between the HLAL patients and normal individuals. It was found that miR-125b was significantly upregulated in HLAL-exo. In addition, the increase of miR-125b level in HSCs or BM-MSCs was induced by HLAL-exo culture (as shown in Figure 3(a)). To determine whether miR-125b participated in the hematopoiesis abnormally induced by HLAL-exo, a miR-125b inhibitor was transfected into CD34+ HSCs or BM-MSCs (as shown in Figures 3(b) and 3(c)). For HSCs, the decrease of CFU colony formation was significantly increased by miR-125b suppression (as shown in Figure 3(d)). Consistent with this, a change of a pattern of hematopoiesis-related gene expression in HSCs can be prevented by miR-125b suppression (as shown in Figure 3(e)). For BM-MSCs, miR-125b suppression can increase the level of CXCL12, IGF1, and SCF, but decreased the level of DKK1 (as shown in Figure 3(f)). The data demonstrated that miR-125b plays a crucial role in the effect of HLAL-exo on hematopoiesis damage.

3.4. BAK1 Is a Target of miR-125b. We used the public database StarBase v2.0 to search for potential target genes of miR-125b. miR-125b can bind to the mRNA sequence of BAK1 on the site of 3′-UTR (as shown in Figure 4(a)). BAK1 protein levels were decreased after HSCs and BM-MSCs cocultured with HLAL-exo (as shown in Figure 4(b)). The result of dual-luciferase assay showed that miR-125b mimic transfection caused a substantial decrease in the luciferase of wild 3′-UTR of BAK1, while the luciferase activity of the mutant sequence of the 3′-UTR of BAK1 had not been impaired by the miR-125b mimic (as shown in Figure 4(c)). We studied the regulatory effect of miR-125b on BAK1 protein level in HSCs and BM-MSCs. Compared with the NC mimic-transfected HSCs and BM-MSCs, miR-125b was upregulated and BAK1 was downregulated after transfection with miR-125b mimic (as shown in Figure 4(d)). Totally, those results demonstrate that BAK1 might be a direct target gene of miR-125b and, thus, mediates effects of HLAL-exo in HSCs and BM-MSCs.

3.5. miR-125b Suppresses Normal Hematopoiesis by BAK1 Regulation. To explore if the effect of miR-125b regulated BAK1 on normal hematopoiesis, we cotransfected miR-125b mimic and si-BAK1 into cells. The levels of miR-125b mRNA decreased in HSCs and BM-MSCs by the si-BAK1 (as shown in Figure 5(a)). Moreover, compared with the miR-125b mimic-transfected HSCs, the expression of α-globulin, γ-globulin, and CSF2 was increased, and the expression of CXCR4 decreased after cotransfection of miR-125b mimic and si-BAK1 (as shown in Figure 5(b)). For BM-MSCs, BAK1 upregulation increases the expression of CXCL12,
Figure 2: Continued.
SCF, and IGF1 and decreases the expression of DKK1. These data indicate that miR-125b affects the normal hematopoietic function of HSC and MSC through BAK1.

4. Discussion

High white blood cell is one of the independent factors of poor prognosis of acute leukemia. When white blood cell count in the peripheral blood exceeds $10^9/L$, it is called hyperleukocytic leukemia (HLAL) [19–21], which accounts for 5% to 20% of acute leukemia. The clinical manifestations are based on primary disease such as leukocyte stasis syndrome, hyperviscosity syndrome, acute tumor lysis syndrome, etc. Patients with HLAL have a high early mortality rate [22], difficulty in complete remission, easy relapse after remission, and difficulty to induce remission after relapse, and it easily induces central nervous system leukemia. Therefore, HLAL is a malignant tumor of the hematopoietic system. The normal hematopoietic process not only requires the self-renewal, proliferation, and differentiation of HSCs [23, 24] but also is related to the hematopoietic microenvironment [25]. Moreover, BM-MSCs play an important role in the maintenance of a stable hematopoietic stem cell pool. The hematopoietic stem cell niche is mainly composed of the supporting bone marrow hematopoietic microenvironment structure [26]. In this paper, we have primarily explored the impact of the HLAL microenvironment on HSCs and BM-MSCs. Exosomes are small vesicles with a diameter of about 30–150 nm secreted by living cells, with a typical lipid bilayer structure [27]. It occurs naturally in body fluids, including blood, saliva, and urine. Exosomes carry important information such as protein, long noncoding RNA (lncRNA) [28], microRNA (miRNA) [29], and messenger RNA (mRNA) [30]. These mechanisms not only play an important role in the transfer of materials and information between cells but also are expected to become multiple markers for early diagnosis of various diseases. Recent studies have shown that exosomes are involved in the development of leukemia [31, 32], affecting cell proliferation and apoptosis, regulating the bone marrow microenvironment, promoting angiogenesis, and inhibiting hematopoiesis. These indicate that exosomes play an important role in the diagnosis and treatment of leukemia. Furthermore, exosomes can participate in regulating the self-renewal, proliferation, and differentiation of hematopoietic cells by carrying miRNAs [33, 34] and affect the normal hematopoietic function. Therefore, we isolated exosomes from peripheral blood samples of HLAL patients and healthy volunteers and explored the effects of exosomes on HSCs and BM-MSCs. Our study found that HLAL-exo affects the hematopoietic differentiation of HSC and the hematopoietic support function of BM-MSC.

Various studies [35, 36] have shown that miR-125b plays a major role in leukemia. Liu et al. [37] found that miR-125b is important in acute myeloid leukemia (AML) and miR-125b promoted MLL-AF9-driven murine AML, revealing the cooperative and dependent relationship between miR-125b and MLL oncogenes. Another study proved that miR-125b regulates the differentiation and reprogramming of T-cell glucose metabolism by directly targeting A20, which is associated with acute lymphoblastic leukemia (ALL) [38]. More importantly, we have determined that miR-125b is highly expressed in HLAL patients through detected. In addition, HSCs and BM-MSCs affected by HLAL-exo have...
Figure 3: Continued.
Figure 3: miR-125b inhibitor restrains the influence of HLAL-derived exosomes. (a) qPCR confirming miR-125b upregulation in HLAL-derived exosomes; ** $p < 0.01$ compared with the NC group. (b), (c) After miR-125b inhibitor intervention, the miR-125b levels in HSCs and BM-MSCs treated with HLAL-exo were detected by RT-PCR; ## $p < 0.01$ compared with the HSC/MSC + HLAL-exo group. (d) CFU assay indicated the effect of transfection with miR-125b inhibitor on the differentiation of HSCs when cocultured with HLAL-exo; ## $p < 0.01$ compared with the HSC+HLAL-exo group. (e) Western blot assay showed the expression of a pattern of hematopoiesis-related genes in HSCs following transfection and HLAL-exo coculture; ** $p < 0.01$ and # $p < 0.05$ compared with the HSC+HLAL-exo group. (f) Western blot analysis performed on hematopoiesis-related genes following the suppression of miR-125b in BM-MSCs. ** $p < 0.01$ compared with the MSC group. ## $p < 0.01$ and # $p < 0.05$, compared with the MSC + HLAL-exo group.
Figure 4: Continued.
Figure 4: The regulatory relationship between miR-125b and BAK1. (a) The targeting relationship and binding site between miR-125b and BAK1 mRNA. (b) BAK1 expression in HSCs and BM-MSCs after treatment with HLAL-exo measured by western blot; *p < 0.01 and †p < 0.05, compared with the HSC/MSC group. (c) Dual-luciferase reporter gene assay verified the targeting relationship between BAK1 and miR-125b in HSCs and BM-MSCs; **p < 0.01 compared with the cotransfection of NC mimic and BAK1wt group. (d) The protein level of BAK1 in HSCs and BM-MSCs after treatment with miR-125b mimic measured by western blot. **p < 0.01 compared with the HSC/MSC group.

Figure 5: Continued.
consistent results, and miR-125b expression is significantly upregulated.

Generally speaking, miRNA regulates mRNA expression by base pairing with target gene mRNA. We used StarBase v2.0 to determine the target gene BAK1 of miR-125b and verified it by using the dual-luciferase reporter gene system and western blot. It was confirmed that HLAL-derived exosomes regulated the hematopoietic differentiation of HSC and hematopoietic support of BM-MSC through miR-125b-BAK1.

5. Conclusions and Future Work

In this paper, we have evaluated and explored the effects of miR-125b, which is carried by HLAL-derived exosomes, on the hematopoietic function of HSCs and BM-MSCs. For this purpose, we have isolated exosomes from the peripheral blood of HLAL patients and healthy volunteers. Then, we measured the level of miR-125b in exosomes and cocultured exosomes with HSCs and BM-MSCs. Moreover, we have used miR-125b inhibitors/mimic for intervention and then measured miR-125b expression and colony forming unit (CFU). Apart from that, HSC and BM-MSC hematopoietic-related factors α-globulin, γ-globulin, CSF2, CRTX4 and CXCL12, SCF, IGF1, and DKK1 expression were measured. Evaluation of the miR-125b and BAK1 targeting relationship, level of miR-125b, and expression of hematopoietic-related genes was performed after patients are treated with miR-125b mimic and si-BAK1. We have observed that miR-125b was upregulated in HLAL-derived exosomes. After HLAL-exosome acts on HSCs, the level of miR-125b is upregulated and affected the expression of α-globulin, γ-globulin, CSF2, and CRCX4. For BM-MSCs, after the action of HLAL-exo, the level of miR-125b is upregulated and reduced CFU and affecting the expression of α-globulin, γ-globulin, CSF2, and CRCX4. Exosomes derived from HLAL carry miR-125b to target and regulate BAK1. Further study confirmed that miR-125b and BAK1 mimic reduced the expression of miR-125b and reversed the effect of miR-125b mimic on hematopoietic-related genes. These results demonstrated that HLAL-derived exosomes carrying miR-125b inhibit the hematopoietic differentiation of HSC and hematopoietic support function of BM-MSC through BAK1.
In future, we are eager to extend the proposed work from different perspectives such as a hybrid model that is formed by combining the proposed model with the existing state-of-the-art model.

Data Availability

The datasets used and analyzed during the current study are available from the corresponding author upon reasonable request.

Conflicts of Interest

The authors declare no conflicts of interest.

Acknowledgments

This study was supported by the Yunnan Applied Basic Research Projects joint fund for applied basic research of Kunming Medical University, Yunnan Provincial Department of Science and Technology, No. 2018FE001(-112); National Natural Science Foundation of China, No. 31460298; Yunnan Applied Basic Research Projects joint fund for applied basic research of Kunming Medical University; and Yunnan Provincial Department of Science and Technology, No. 2018FE001 (-113).

References

[1] C. Ganzel, J. Becker, P. D. Mintz, H. M. Lazarus, and J. M. Rowe, “Hyperleukocytosis, leukostasis and leukapheresis: practice management,” Blood Reviews, vol. 26, no. 3, pp. 117–122, 2012.

[2] V. Villgran, M. Agha, A. Raptis et al., “Leukapheresis in patients newly diagnosed with acute myeloid leukemia,” Transfusion and Apheresis Science, vol. 55, no. 2, pp. 216–220, 2016.

[3] C. Rollig and G. Ehninger, “How I treat hyperleukocytosis in acute myeloid leukemia,” Blood, vol. 125, no. 21, pp. 3246–3252, 2015.

[4] S. Giammarco, P. Chiusolo, N. Piccirillo et al., “Hyperleukocytosis and leukostasis: management of a medical emergency,” Expert Review of Hematology, vol. 10, no. 2, pp. 147–154, 2017.

[5] D. Lucas, “The bone marrow microenvironment for hematopoietic stem cells,” Advances in Experimental Medicine & Biology, vol. 1041, pp. 5–18, 2017.

[6] N. Asada, S. Takeishi, and P. S. Frenette, “Complexity of bone marrow hematopoietic stem cell niche,” International Journal of Hematology, vol. 106, no. 1, pp. 45–54, 2017.

[7] V. W. Yu and D. T. Scadden, “Hematopoietic stem cell and its bone marrow niche,” Current Topics in Developmental Biology, vol. 118, pp. 21–44, 2016.

[8] S. J. Morrison and D. T. Scadden, “The bone marrow niche for hematopoietic stem cells,” Nature, vol. 505, no. 7483, pp. 327–334, 2014.

[9] M. Yamashita, P. V. Dellorusso, O. C. Olson, and E. Passegue, “Dysregulated hematopoietic stem cell behaviour in myeloid leukaemogenesis,” Nature Reviews Cancer, vol. 20, no. 7, pp. 365–382, 2020.

[10] A. Wang and H. Zhong, “Roles of the bone marrow niche in hematopoiesis, leukaemogenesis, and chemotherapy resistance in acute myeloid leukemia,” Hematology (Amsterdam, Netherlands), vol. 23, no. 10, pp. 729–739, 2018.

[11] B. Apollonio and A. G. Ramsay, “Exosomes and CAFs: partners in crime,” Blood, vol. 126, no. 9, pp. 1053–1055, 2015.

[12] D. Prieto, N. Sotelo, N. Seija et al., “S100-A9 protein in exosomes from chronic lymphocytic leukemia cells promotes NF-κB activity during disease progression,” Blood, vol. 130, no. 6, pp. 777–788, 2017.

[13] B. Kumar, M. Garcia, L. Weng et al., “Acute myeloid leukemia transforms the bone marrow niche into a leukemia-permissive microenvironment through exosome secretion,” Leukemia, vol. 32, no. 3, pp. 575–587, 2018.

[14] N. Jafarzadeh, Z. Safari, M. Pournour, N. Amirizadeh, M. Forouzandeh Moghadam, and M. Sadeghizadeh, “Alteration of cellular and immune-related properties of bone marrow mesenchymal stem cells and macrophages by K562 chronic myeloid leukemia cell derived exosomes,” Journal of Cellular Physiology, vol. 234, no. 4, pp. 3697–3710, 2019.

[15] M. Yáñez-Mo, P. R. Siljander, Z. Andreu et al., “Biological properties of extracellular vesicles and their physiological functions,” Journal of Extracellular Vesicles, vol. 4, Article ID 27066, 2015.

[16] R. Hanayama, “Emerging roles of extracellular vesicles in physiology and disease,” Journal of Biochemistry, vol. 169, no. 2, pp. 135–138, 2020.

[17] C. Zhao, F. Du, Y. Zhao, S. Wang, and L. Qi, “Acute myeloid leukemia cells secrete microRNA-4532-containing exosomes to mediate normal hematopoiesis in hematopoietic stem cells by activating the LDOC1-dependent STAT3 signaling pathway,” Stem Cell Research & Therapy, vol. 10, no. 1, p. 384, 2019.

[18] S. Haque and S. R. Vaiselbuh, “Silencing of exosomal miR-181a reverses pediatric acute lymphocytic leukemia cell proliferation,” Pharmaceuticals, vol. 13, no. 9, p. 241, 2020.

[19] S. Bertoli, M. Picard, E. Berard et al., “Dexmethylasone in hyperleukocytic acute myeloid leukemia,” Haematologica, vol. 103, no. 6, pp. 988–998, 2018.

[20] Y. L. Liu, H. B. Liu, W. J. Wang, L. Ma, X. N. Wang, and H. S. Liu, “[Analysis of bone marrow and peripheral blood cytologic features in hyperleukocytic acute leukemia],” Zhongguo Shi Yan Xue Ye Xue Za Zhi, vol. 21, no. 3, pp. 562–566, 2013.

[21] N. L. Haas, A. Nafday, J. A. Cranford, S. E. Yentz, D. L. Bixby, and B. S. Bassin, “Implementation of a multidisciplinary care pathway via an emergency department-ICU to improve care of emergency department patients presenting with leukostasis,” Crit Care Explor, vol. 2, no. 2, Article ID e0084, 2020.

[22] A. M. Ali, A. E. Mirrakhimov, C. N. Abboud, and A. F. Cashen, “Leukostasis in adult acute hyperleukocytic leukemia: a clinician’s digest,” Hematological Oncology, vol. 34, no. 2, pp. 69–78, 2016.

[23] D. Carroll and D. K. St Clair, “Hematopoietic stem cells: normal versus malignant,” Antioxidants and Redox Signaling, vol. 29, no. 16, pp. 1612–1632, 2018.

[24] S. E. Koschade and C. H. Brandsd, “Selective autophagy in normal and malignant hematopoiesis,” Journal of Molecular Biology, vol. 432, no. 1, pp. 261–282, 2020.

[25] A. C. Ribeiro-Filho, D. Levy, J. L. M. Ruiz, M. D. C. Mantovani, and S. P. Bydlowski, “Traditional and advanced cell cultures in hematopoietic stem cell studies,” Cells, vol. 8, no. 12, p. 1628, 2019.

[26] H. Li, R. Ghazanfari, D. Zacharaki, H. C. Lim, and S. Scheding, “Isolation and characterization of primary bone marrow mesenchymal stromal cells,” Annals of the New York Academy of Sciences, vol. 1370, no. 1, pp. 109–118, 2016.
[27] R. Kalluri and V. S. LeBleu, “The biology, function, and biomedical applications of exosomes,” *Science*, vol. 367, no. 6478, 2020.

[28] S. Li, Y. Li, B. Chen et al., “exoRBase: a database of circRNA, lncRNA and mRNA in human blood exosomes,” *Nucleic Acids Research*, vol. 46, no. D1, pp. D106–d112, 2018.

[29] J. Lin, J. Li, B. Huang et al., “Exosomes: novel biomarkers for clinical diagnosis,” *ScientificWorldJournal*, vol. 2015, Article ID 657086, 2015.

[30] L. Barile and G. Vassalli, “Exosomes: therapy delivery tools and biomarkers of diseases,” *Pharmacology & Therapeutics*, vol. 174, pp. 63–78, 2017.

[31] M. Boyiadzis and T. L. Whiteside, “Exosomes in acute myeloid leukemia inhibit hematopoiesis,” *Current Opinion in Hematology*, vol. 25, no. 4, pp. 279–284, 2018.

[32] J. Paggetti, F. Haderk, M. Seiffert et al., “Exosomes released by chronic lymphocytic leukemia cells induce the transition of stromal cells into cancer-associated fibroblasts,” *Blood*, vol. 126, no. 9, pp. 1106–1117, 2015.

[33] R. Mardani, M. H. Jafari Najaf Abadi, M. Motieian et al., “MicroRNA in leukemia: tumor suppressors and oncogenes with prognostic potential,” *Journal of Cellular Physiology*, vol. 234, no. 6, pp. 8465–8486, 2019.

[34] S. Taverna, S. Fontana, F. Monteleone et al., “Curcumin modulates chronic myelogenous leukemia exosomes composition and affects angiogenic phenotype via exosomal miR-21,” *Oncotarget*, vol. 7, no. 21, pp. 30420–30439, 2016.

[35] Y. M. Deng, A. L. Luo, G. F. Li, M. S. Cai, L. Xu, and M. X. Yan, “[Down-Regulation of MiR-125b reverses drug resistance of doxorubicin-resistant leukemia cells],” *Zhongguo Shi Yan Xue Ye Xue Za Zhi*, vol. 26, no. 6, pp. 1610–1615, 2018.

[36] M. Bousquet, M. H. Harris, B. Zhou, and H. F. Lodish, “MicroRNA miR-125b causes leukemia,” *Proceedings of the National Academy of Sciences of the U S A*, vol. 107, no. 50, pp. 21558–21563, 2010.

[37] J. Liu, B. Guo, Z. Chen et al., “miR-125b promotes MLL-AF9-driven murine acute myeloid leukemia involving a VEGFA-mediated non-cell-intrinsic mechanism,” *Blood*, vol. 129, no. 11, pp. 1491–1502, 2017.

[38] Z. Liu, K. R. Smith, H. T. Khong et al., “miR-125b regulates differentiation and metabolic reprogramming of T cell acute lymphoblastic leukemia by directly targeting A20,” *Oncotarget*, vol. 7, no. 48, pp. 78667–78679, 2016.